Aachen, Germany (ots) - Grünenthal announced today that the first healthy volunteers have been enrolled in a Phase I trial of its voltage-gated sodium channel (NaV) 1.8 inhibitor. The orally administered investigational medicine aims to provide a non-opioid therapy option across a range of acute and chronic pain conditions. Full results of the trial are expected in ...
Schweizerischer Nationalfonds / Fonds national suisse
Tübingen, Germany (ots) - Acousia Therapeutics GmbH, a clinical-stage biotechnology company developing treatments for acute and chronic inner ear hearing loss, announced the completion of patient enrollment in its Phase 2 PROHEAR clinical study. ACOU085 (INN: Bimokalner) is a proprietary, first-in-class small ...
Suresnes, France (ots/PRNewswire) - - Servier acquires KER-0193, a potential treatment for Fragile X syndrome, developed by Kaerus Bioscience, a Medicxi company - KER-0193, a novel, orally bioavailable small molecule, was granted Orphan Drug Designation and Rare Pediatric Drug Designation by U.S. FDA - Acquisition ...
Aachen (ots) - Grünenthal PRO, the contract development and manufacturing organization (CDMO) division of Grünenthal offering a range of services including final assembly of autoinjectors, is entering into a non-exclusive partnership with SHL Medical, a world-leading solutions provider of advanced drug delivery ...
Brussels (ots/PRNewswire) - - 26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing research for people living with epilepsies - Data include an open-label extension study describing the long-term safety of FINTEPLA®▼ (fenfluramine)[1] and global functioning ...
London and Boston (ots/PRNewswire) - Precision oncology leader joins world-class team as company enters next phase of translating AI-driven drug discovery into life-changing medicines. Isomorphic Labs, the AI-first drug discovery company, has announced the appointment of Ben B. Wolf, M.D., Ph.D., as Chief Medical Officer. Dr. Wolf will be based in the company's newly ...
Porto, Portugal (ots/PRNewswire) - BIAL, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, today announced that it will give an oral presentation on its potential disease-modifying compound, BIA 28-6156, at the GBA1 Meeting 2025 being held June 5-7, 2025, in Montreal, Canada. The GBA1 Meeting 2025 is hosted by McGill University, focusing on all aspects of GBA1 research, from basic ...
Aachen, Germany (ots) - - Grünenthal announces that it agreed to acquire the commercial rights to Cialis® from Eli Lilly and Company in Mexico, Brazil and Colombia, further strengthening Grünenthal's footprint in Latin America. - As part of the acquisition, Grünenthal will transfer the manufacturing of Cialis® to its production site in Chile. - Since 2017, ...
Zurich (ots) - The Astrasana Group is pleased to announce that its subsidiary, Astrasana Pharma AG, has been granted the official cultivation license for medical cannabis by Swissmedic. This authorization permits the controlled cultivation of cannabis plants with a THC content above 1% and marks an important milestone in the expansion of the Group's pharmaceutical ...
Aachen (ots) - Maren Thurow has today assumed the role of Vice President and Head Global Communications at Grünenthal. She succeeds Florian Dieckmann, who has played a key role in evolving the company’s Communications department since 2021. In her new position, Maren will oversee Grünenthal’s communications operations across all markets and lead the team based at ...
Tübingen, Germany (ots) - Acousia Therapeutics GmbH announced that it has successfully enrolled 50% of patients in its ongoing Phase 2 clinical trial, the PROHEAR Study, evaluating ACOU085 (INN: bimokalner) for the prevention of cisplatin-induced hearing loss in patients with testicular cancer undergoing chemotherapy. Cisplatin is a cornerstone in modern oncology and ...
Jerusalem (ots/PRNewswire) - - Results from phase 2a trial in ALS patients were published in Muscle and Nerve. - Statistically significant 58% to 64% slower ALSFRS-R progression rate in IPL344-treated patients compared to the matched PRO-ACT records. - NfL was reduced by 27% for patients treated for at least two months. - Unadjusted median survival for participants in ...
London (ots/PRNewswire) - Isomorphic Labs will utilise the funding to further power its AI drug design engine through frontier AI research and development and to scale and progress its drug candidate pipeline. Isomorphic Labs, an AI-first drug design and development company, today announced it has raised $600 ...
London (ots/PRNewswire) - Isomorphic Labs will utilise the funding to further power its AI drug design engine through frontier AI research and development and to scale and progress its drug candidate pipeline. Isomorphic Labs, an AI-first drug design and development company, today announced it has raised $600 ...
Aachen, Germany & Toronto, Canada, (ots) - Grünenthal, a global leader in pain management and related diseases, and Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, announced today that they have entered into a strategic licensing agreement whereby Apotex will have the exclusive Canadian rights to Qutenza®, a topical, non-systemic, ...
London (ots/PRNewswire) - Following the licensing agreement with X4 Pharmaceuticals, Norgine is pleased to see the announcement from X4 today that their Marketing Authorization Application (MAA) for mavorixafor for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis), a rare ...
London (ots/PRNewswire) - Keith Hale has been appointed as Group CEO of Titian Software and Labguru (BioData Inc.), two leading providers of laboratory data management solutions, as part of the goal to accelerate the future of digital lab operations. A well-known fintech executive, Keith brings 33 years of growth-focused software and technology leadership. He ...
Porto, Portugal (ots/PRNewswire) - BIAL, a hundred-year-old innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, announced that the first patient has completed the full dose regimen in the ACTIVATE Phase 2 study. BIA 28-6156 is a first-in-class, small molecule for once-daily oral ...
London (ots/PRNewswire) - Back to media releases Next media release Norgine today announced that it completed its marketing authorisation application filing to European Medicines Agency (EMA) for eflornithine in high-risk neuroblastoma (HRNB). This follows the submissions in April 2024, via Project Orbis, in ...
London (ots/PRNewswire) - - Accord announces that the European Commission (EC has granted marketing authorisation for Imuldosa® (development code: DMB-3115), a biosimilar to Stelara®, indicated for a range of immune medicated inflammatory diseases. - The EC approval follows a positive opinion issued on 19 October ...
Strides Pharma International AG
Aachen, Germany/Morristown, N.J. (ots) - - The Phase III trial AV001 aims to evaluate QUTENZA® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures[1], thus affecting more than 3 million people with surgical procedures ...
Aachen, Germany (ots) - Today, Grünenthal announced that the first participants have been enrolled in a first-in-human Phase I clinical trial for a nociceptin (NOP) receptor agonist. The trial will include 90 healthy volunteers and aims to demonstrate a favourable safety and tolerability profile and to confirm the ...
Caesarea, Israel (ots/PRNewswire) - Epitomee Medical Ltd. (TASE: EPIT) announces today that the company leadership intends to present Epitomee's Oral Delivery of Biologics Platform at the 14th Annual PODD Conference - Partnership Opportunities in Drug Delivery, taking place in Boston, MA, October 28-29, 2024. ...
Caesarea, Israel (ots/PRNewswire) - Epitomee's Ingestible Capsule, Offers a Safe and Effective Prescription Solution for Adults with BMI of 25-40 looking for Alternative Drug Free Solutions for Their Weight Management Needs alongside diet and exercise. Epitomee Medical Ltd. (TASE: EPIT), announced that the United States Food and Drug Administration (FDA) has officially ...
Ejby, Denmark (ots/PRNewswire) - Today Scantox, together with its majority owner Impilo, finalized the acquisition of Gentronix Ltd, a UK based GLP compliant genetic toxicology Contract Research Organization ("CRO"). Gentronix, now integrated into Scantox Group, is well recognized for its high-quality genetic toxicology services and strong scientific engagement, with ...
INSIGHTEC; Charles River Laboratories International, Inc.
Wilmington, Mass., Miami and Haifa, Israel (ots/PRNewswire) - Collaboration stands to advance novel therapeutic applications across multiple neurologic conditions Charles River Laboratories International, Inc. (NYSE: CRL) and Insightec, a global healthcare company dedicated to using focused ultrasound to transform ...
Tübingen, Germany (ots) - Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, will be presenting the ACOU085 Phase 2 PROHEAR clinical study at the HansonWade 4th Inner Ear Disorders Therapeutics Summit in Boston (MA) from August ...